Anavex Life Sciences Corp (AVXL)

[frrol]

Agree. I think the company does a disservice by focusing on S1 agonism, given 2-73 is (apparently from some research) not a potent agonist relative to other known compounds. That research could be just incomplete of course, or even flawed. Nevertheless, I suspect 2-73 effectiveness would reside in its pluripotent agonism, which the company or any independent research hasn't really established. They've gotten hints of it. But what the company is doing right is pushing to prove efficacy, which is where the proverbial rubber hits the road. Which is why an update on the Part C, or start of the Phase 2/3, or results from the Rett Phase 2, are so anticipated.